PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Istituto Europeo di Oncologia, IRCCS, Department of Early Drug Development, Italy; University of Milano, Milano, Italy. Electronic address: giuseppe.curigliano@ieo.it.\', \'Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Portugal; Nova Medical School, Lisbon, Portugal.\', \'Iridium Kankernetwerk, Department of Radiation Oncology, Wilrijk-Antwerp, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Wilrijk-Antwerp, Belgium.\', \'Breast Surgery, San Raffaele University and Research Hospital, Milano, Italy.\', \'Istituto Europeo di Oncologia, IRCCS, Department of Early Drug Development, Italy; University of Milano, Milano, Italy.\', \'Faculty of Medicine and Health, Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia.\', \'Service Interdisciplinaire de Cancérologie, Hopital Riviera-Chablais, Rennaz, Vaud, Geneva University Hospitals, Swiss Group for Clinical Cancer Research (SAKK), Switzerland.\', \'Medical University of Gdansk, Gdansk, Poland.\', \'Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Portugal.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0960-9776(20)30093-X10.1016/j.breast.2020.04.006
?:hasPublicationType
?:journal
  • Breast (Edinburgh, Scotland)
is ?:pmid of
?:pmid
?:pmid
  • 32334323
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all